You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

613 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Aug 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    dexamethasone
Aug 2024
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Oct 2024
Regimen
Intent: Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative, Adjuvant
Jan 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Aug 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Curative
May 2019
Drug
Other Name(s): Lonsurf®
Nov 2024
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Jun 2024
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    megestrol - oral tablets
ODB - General Benefit
    tamoxifen
May 2019

Pages